Galapagos « Terug naar discussie overzicht

Koers Galapagos 2012

3.189 Posts, Pagina: « 1 2 3 4 5 6 ... 84 85 86 87 88 89 90 91 92 93 94 ... 156 157 158 159 160 » | Laatste

Omlaag ↓

[verwijderd] 20 juli 2012 12:33

www.biofocus.com/our-science/drugdisc...

A drug discovery success

Dear readers,

A CRO like BioFocus which engages in drug discovery for our clients has a number of success measures – some are financial - a profitable company is good for continuity and shareholders (Galapagos) and also good for the organizations with which we work – a financially stable organization gives comfort to both our suppliers and clients.

However, the success measure most interesting to our clients is the number and quality of candidate medicines that BioFocus delivers. We can now report on a major drug discovery success in which BioFocus has been engaged.

In November 2006, a new collaboration was publically revealed between BioFocus and the not-for-profit organization: Institute for One WorldHealth (iOWH). In this collaboration, iOWH engaged BioFocus to perform the chemistry, screening and ADME studies in a partnership to design, make and test compounds that would be a cure for diarrhea, particularly diarrhea caused by cholera toxin. The particular biological target, the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is a chloride ion channel found in the lung and gut. In the lung (and in defective form) the channel is responsible for cystic fibrosis. In the gut (and when over-activated by cholera toxin) it causes unregulated outflow of ions (and water) – an adult can lose 40L of water per day in some cases. Death – particularly of infants can occur within hours. Around two million people die from cholera-induced diarrhea every year.

With some early hit molecules emanating from the laboratories of UCSF (Professor A. Verkman) showing that the channel could be negatively modulated, the challenge was on to design and validate robust biochemical and cellular assays to evaluate compounds, and to turn the hit molecules into viable leads for progression to drugs. The ion channel biology expertise and a chemistry design team at BioFocus in Chesterford Park worked for three and a half years to generate molecules with in vivo activity and to get acceptable PK parameters. Many avenues were explored during the collaboration, including a very large HTS screen to search for new chemotypes. The work eventually revealed a clinical candidate iOWH032, a compound that has now gained IND approval for first-in-man administration. This was announced by iOWH on 1 March 2011.

This short article, by its size, cannot describe all the challenges that the teams had to overcome. BioFocus had to engage with many organizations besides iOWH – including the University of Pittsburgh in the USA and CROs in China. Some elements of the project have now been revealed, commencing with a poster presented by Kevin Doyle at the 21st International Symposium on Medicinal Chemistry in Brussels, Belgium, 5-9 September 2010. Details of the poster can be found on the iOWH website.

A lecture was given in India at the joint RSC/IICT conference in Hyderabad on 26 February 2011 by me. This presentation will be given again in the UK: first at the SCI sponsored “Young Chemist in Industry” meeting to be held in London on 9 May 2011 by Carrie-Anne Molyneaux and then at the 22nd East-of-England symposium on medicinal chemistry to be held in Hatfield on 19 May 2011 by Kevin Doyle.

The reception to the project success at the Hyderabad conference (India could of course be one of the major beneficiaries of this project) was incredibly supportive – I do not recollect BioFocus being named the “Mother Theresa of drug discovery”, before. Below is a picture of the author at the conference.

The iOWH provided coordination and direction from Eugenio de Hostos, Tue Nguyen and David Brown.

The BioFocus team was: Kevin Doyle, Graham Jones, Joanne Peach, Michael Russell, Stephen Penrose, Amanda Van de Poël, Carrie-Anne Molyneaux, Jackie Macritchie, Angus MacLeod, Sebastian Brückner, Joanne Shearer, David Cronk, Gary Clark, Alan Beresford, Ian Gowers, Simon Dowler, Richard Martin, Carmela Clark, Suzie Clarke, Scott Maidment and Matthew Gardener.

[verwijderd] 20 juli 2012 12:35

www.argentadiscovery.com/about/client...

Clients & Testimonials

Clients

Argenta works with a wide variety of companies of differing sizes and geographic locations. Some examples of recent clients are listed below.
•Genentech (South San Francisco, USA)
In the course of six major drug discovery collaborations, scientists from Argenta and Genentech are applying their expertise in medicinal and computational chemistry, biochemistry and DMPK to discover NCEs acting against undisclosed drug targets.
•Janssen Pharmaceutica (Belgium)
As part of a fully integrated drug discovery service agreement, Argenta is providing medicinal chemistry and biology services for a number of Janssen oncology projects with the aim of delivering novel cancer drug candidates. Argenta is performing hit-to-lead, lead optimization and additional activities up to pre-clinical candidate selection. This is a multi-year, multi-target collaboration with the initial phase covering a five-year period, and the number of targets is extendable up to 15.
•AstraZeneca (USA, Sweden and UK)
Argenta has provided discovery research capabilities to various groups within AstraZeneca. The most recent project involves a team of scientists from the two companies collaborating to identify long acting muscarinic (M3) antagonists (LAMAs) and dual acting muscarinic antagonist-beta2 agonist (MABA) candidate drugs.
•Corcept Therapeutics (Menlo Park, CA, USA)
Corcept and Argenta are collaborating to discover novel antagonists of the Glucocorticoid receptor for the treatment of Cushing's syndrome, psychotic depression as well as metabolic diseases including diabetes, obesity and hypertension. Using their medicinal chemistry, assay development and screening, CADD and ADME capabilities, Argenta has delivered three distinct patented series, and a first development candidate CORT108297 entered Phase I trials in Q1 2010. In animal models, CORT108297 has demonstrated the ability to prevent and reverse weight gain caused by treatment with multiple anti-psychotic drug regimens.
•Almac Discovery (Craigavon, UK)
Scientists from Argenta and Almac worked together to advance one of Almac's cancer programmes. Argenta provided medicinal chemistry, CADD and ADME services and know-how, and Almac contributed medicinal chemistry, biochemistry and in vitro screening capabilities and expertise.
•Zafgen (Cambridge, USA)
Scientists from the two companies are exploiting Argenta's expertise in medicinal and computational chemistry, biochemistry, in vitro screening, and DMPK to accelerate development candidate nomination for one of Zafgen's innovative therapeutics programmes for obesity.
•BioTie Therapies Corp. (Turku, Finland)
During a lead optimisation collaboration, scientists from the two companies exploited Argenta's expertise in medicinal and computational chemistry to advance one of BioTie's novel therapeutics programmes towards development candidate nomination.
•CellCentric (Cambridge, UK)
Under the terms of the agreement, scientists from the two companies are exploiting Argenta's expertise in virtual screening, molecular biology, biochemical assay development and in vitro screening to discover inhibitors for a number of potential epigenetic-related therapeutic targets.
•Novartis
In a two-year drug discovery collaboration, an integrated team of Argenta and Novartis scientists worked on a programme that centred on the search for new diabetes therapies.

Testimonials

"Argenta has made a major contribution to our discovery program. We surveyed many possibilities for partnering our medicinal chemistry including groups in Europe, China, and India, and chose Argenta for the quality of their proposal, the calibre of their leadership, and the cost-effectiveness of their work. As a more virtual company we really rely on our partners for input and direction. Their extensive pharmaceutical industry experience has proven to be invaluable to moving our program forward. They have allowed us to integrate most of our discovery efforts – including chemistry, biology and ADME - under one roof, resulting in very efficient data turnaround and speedy decision making. They have hit all of the project milestones on time or ahead of schedule. I couldn’t imagine we would be as far along if we partnered with anyone else."

"We chose to work with Argenta on our collaborative drug discovery programme as from our first meeting they demonstrated attention to scientific detail, were extremely pro-active in assessing opportunities, and turned proposals around quickly. As the collaboration developed, the overriding sense was that Argenta consistently delivered, in terms of overcoming chemistry challenges to allow delivery of final compounds, in highlighting druggability issues with compounds, and in designing and synthesising new targets to test and overcome these issues. The team was extremely professional in its approach, very pragmatic with regard to drug discovery, and productive. The interpersonal aspects of the relationship were excellent, and it was an extremely enjoyable, as well as productive collaboration. Argenta's strapline is innovation..., expertise..., delivered, and I think this summarises very well the strengths of Argenta, and the value which we derived from working with them"

"Argenta Discovery has been a terrific partner in every facet of our discovery chemistry work. They did careful, creative work on time and on budget. In addition to having great bench chemists, their business process emphasizes clear and continuous communication, which was helpful at every stage. In our specific case, they solved a chemistry problem that had stumped many large companies and led to three patented series of new chemical entities. I cannot imagine a better vendor!"

"I have had the pleasure of working with Argenta as part of a drug discovery research collaboration. The project entails complex synthetic chemistry and molecular modeling, and involves the need for a wide range of pharmacology and ADME assays/models. Argenta not only brought these capabilities under one roof but also brought a level of expertise, understanding, reliability and professionalism that has permitted rapid progress toward our goals. After working at both big pharma and with biotech, I can attest that the experience with Argenta offers the best of both."

Gebraden Kip 20 juli 2012 17:08

RT 14,85.
Ben ik even blij dat ik, nadat ik gisteren de helft had verkocht, deze zelfde helft 5 uur later toch weer terug heb gekocht.
Kostte me wel 100 EUR extra, maar ja.

trab33 20 juli 2012 17:11

als je gebraden wordt moet je stil blijven zitten
koers zegt veel vandaag bij zo'n sentiment

[verwijderd] 22 juli 2012 17:06

Wat een ontzettend mooi weer vandaag!

Op 22 augustus is er een meeting, maar ik heb het nog niet op het forum voorbij zien komen. Het pdf lijkt van 17 juli te zijn.

Extraordinary General Shareholders’ Meeting | 22 August 2012
Galapagos convenes its Extraordinary General Shareholders' Meeting at its registered office in Mechelen, Belgium on Wednesday 22 August 2012 at 11:00 a.m. CET. The agenda and other documents for this EGM are available below.

glpg site:
www.glpg.com/index.php/companyovervie...

directe link naar pdf:
www.glpg.com/index.php/download_file/...

[verwijderd] 22 juli 2012 17:34

Het betreft hier een BAVA waarop de toekenning van warrants/opties aan het management wordt besproken en besloten. Lijkt mij geen schollend item.
Zoef

[verwijderd] 23 juli 2012 09:06

Hopen op weer een enerverend weekje!

K. Wiebes 23 juli 2012 12:06

Je wordt op je wenken bediend.

Maar ik geloof niet dat je dít in gedachten had.

[verwijderd] 23 juli 2012 12:52

quote:
Mo Ney schreef op 14 juli 2012 20:38:
[...]
Ik zal je me aankoopgemiddelde besparen(anders wordt je wellicht groen en geel...)
Over z'on 3 weken komt er een leuk bedrag vrij, vandaar die 8 euro.
Vergeet niet dat de koers, puur door de crisis, op 2,88 heeft gestaan...

Nou....wie weet kan ik ze toch nog voor een leuk prijsje bijkopen, het algehele sentiment heeft toch weer invloed op de koers van Galapagos(raar, maar waar...).
Een dag voor de cijfers kan ik weer een leuk portie bijkopen, begrijp me niet verkeerd, de koers mag van mij ook naar wat realistischere koersnivo's(20 euro).
Wie weet komt er voor die tijd nog wat leuk nieuws uit het Galapagos-kamp..

Fijne en zonnige dag!

[verwijderd] 23 juli 2012 12:55

1 4,847 13.89 Bied
1 4,618 14,10 Laat

Deze beste man/vrouw/computer heeft het er maar druk mee...

www.euronext.com/trader/advancedmarke...

egeltjemetstekel 23 juli 2012 13:11

ach mischien ook bovenop t algemene sentiment nog koersdruk van n grote jongen
die goedkoop in wil stappen??
dat kunnen we best hebben

[verwijderd] 23 juli 2012 20:14

Wat een heerlijke dag, hè!
Eindelijk zomer!

Fijne avond, proost!

[verwijderd] 24 juli 2012 09:13

Opening, na het goede nieuws van vandaag, valt me tegen.
Mooie prestatie wederom van Galapagos, ben er blij mee.
Ik ga straks richting de kust, beetje genieten van deze zomerse dag!
Wens een ieder een fijne dag.

Gebraden Kip 24 juli 2012 10:33

RT 14,70

Gebraden Kip 24 juli 2012 10:46

ATH 14,87

[verwijderd] 24 juli 2012 11:10

Dit zijn wel heel saaie berichten, kom maar terug boven de 15 of met een constructieve bijdrage.

Gebraden Kip 24 juli 2012 11:45

quote:
De Maanman schreef op 24 juli 2012 11:10:
Dit zijn wel heel saaie berichten, kom maar terug boven de 15 of met een constructieve bijdrage.

Dit is het koersdraadje van Galapagos.
Maar je hoeft het niet te lezen hoor.
Laat staan dat je erop moet reageren.

[verwijderd] 24 juli 2012 13:02

Laatste kans om onder de 15 te kopen, uitbraak is aanstaande kan ook niet anders met zulke berichten, ik zeg ooievaar heeft gelijk

Loureiro 25 juli 2012 13:42

quote:
De Maanman schreef op 24 juli 2012 13:02:
Laatste kans om onder de 15 te kopen, uitbraak is aanstaande kan ook niet anders met zulke berichten, ik zeg ooievaar heeft gelijk

Opnieuw een koper stukken aan het verzamelen? Koers gaat alleszins opnieuw richting 15 euro.

[verwijderd] 25 juli 2012 13:46

precies het beeld van gister,, eerst een flinke daling, om vervolgens weer rond 14,75 uit te komen

3.189 Posts, Pagina: « 1 2 3 4 5 6 ... 84 85 86 87 88 89 90 91 92 93 94 ... 156 157 158 159 160 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	5 feb 2025 17:35
Koers	21,860
Verschil	-0,160 (-0,73%)
Hoog	22,000
Laag	21,760
Volume	70.959
Volume gemiddeld	112.201
Volume gisteren	94.575

Galapagos nieuws

23 jan	Barclays zet Galapagos op de verkoopl...
19 jan	IMCD uitblinker op goedgeluimd Damrak
09 jan	Van Lanschot: belangrijkste wending o...
08 jan	Mat begin beursdag vol nieuws van Gal...
08 jan	Galapagos wil opsplitsen in twee beur...	1
07 dec	Galapagos: bemoedigende nieuwe result...
20 nov	Kepler Cheuvreux zet Galapagos op ver...
05 nov	Klinische resultaten Galapagos steune...
04 nov	Deutsche Bank verlaagt koersdoel Gala...
02 nov	Financials en Shell doen goede zaken ...

Meer ››